Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News AstraZeneca ADR Representing 0.5 Ord Shs AZN

Consumer Cyclical Healthcare Advertising Agencies
AstraZeneca PLC is a science-led biopharmaceutical company. It discovers, develops, and commercializes prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, respiratory and immunology and vaccines and immune therapies. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex... see more

Recent & Breaking News (NDAQ:AZN)

AstraZeneca and Merck present final results of key secondary overall survival endpoint from Phase III PROpel trial at ASCO GU Cancers Symposium

Business Wire February 16, 2023

TEZSPIRE® approved for self-administration in the US with a new pre-filled pen

Business Wire February 2, 2023

AstraZeneca Begins Tender Offer to Acquire CinCor Pharma, Inc.

Business Wire January 23, 2023

HUTCHMED Announces Agreement with NHSA for Inclusion of ORPATHYS® in the National Reimbursement Drug List in China

GlobeNewswire January 18, 2023

AIRSUPRA(TM) (PT027) approved in the US for asthma

Business Wire January 11, 2023

SHAREHOLDER ALERT: Weiss Law Investigates CinCor Pharma, Inc.

PR Newswire January 9, 2023

Tempus Announces Prospective Study for Biomarker Discovery in Small Cell Lung Cancer

Business Wire January 5, 2023

AstraZeneca Awards $4M to Nonprofit Organizations to Advance Health Equity

Business Wire December 13, 2022

Camizestrant Significantly Delayed Disease Progression in Advanced ER-Positive Breast Cancer, Adding at Least 3.5 Months Benefit Versus FASLODEX® (fulvestrant)

Business Wire December 8, 2022

Capivasertib Plus FASLODEX® (fulvestrant) Reduced the Risk of Disease Progression or Death by 40% Versus FASLODEX in Advanced HR-Positive Breast Cancer

Business Wire December 8, 2022

ENHERTU® (fam-trastuzumab deruxtecan-nxki) Achieved Statistically Significant Overall Survival, Reducing the Risk of Death by 36% Vs. Trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Breast cancer in DESTINY-Breast03

Business Wire December 7, 2022

AstraZeneca Showcases Strength of Hematology Portfolio and Pipeline Across Multiple Hard-to-Treat Conditions at ASH 2022

Business Wire November 30, 2022

C4X Discovery Holdings plc: C4XD signs exclusive global licence worth up to $402 million¹ with AstraZeneca for the development and commercialisation of NRF2 Activator programme

GlobeNewswire November 28, 2022

AstraZeneca Aims to Redefine Breast Cancer Care With New Data Across the Treatment Spectrum At SABCS 2022

Business Wire November 22, 2022

Alexion, AstraZeneca Rare Disease, Completes Acquisition of LogicBio® Therapeutics

Business Wire November 16, 2022

IMFINZI and IMJUDO with chemotherapy approved in the US for patients with metastatic non-small cell lung cancer

Business Wire November 11, 2022

AstraZeneca EVUSHELD Named on TIME's List of the Best Inventions of 2022

Business Wire November 10, 2022

PT027 Recommended by FDA Advisory Committee as New Rescue Treatment for Asthma

Business Wire November 9, 2022

ULTOMIRIS® (ravulizumab-cwvz) showed zero relapses in adults with neuromyelitis optica spectrum disorder (NMOSD) with median treatment duration of 73 weeks

Business Wire October 27, 2022

Camizestrant Significantly Improved Progression-free Survival Vs. FASLODEX® (fulvestrant) in SERENA-2 Phase II Trial in Advanced ER-positive Breast Cancer

Business Wire October 26, 2022